Long R3 IGF-1 (LR3-IGF-1)
IGF-1 LR3, Long R3 IGF-I, LR3-IGF-1, LONG R3 IGF-I, Long Arg3 IGF-I, Long [Arg3]-IGF-I
Long R3 IGF-1 is a laboratory-engineered version of human insulin-like growth factor 1, redesigned so that it escapes the binding proteins that normally hold IGF-1 in check. It was created as a cell-culture reagent for biopharmaceutical manufacturing, and that is still its only legitimate use. Despite being widely sold online for muscle growth, it has never been tested in a human clinical trial.
Mechanism
Native IGF-1 is not a free-floating hormone. More than 98% of it circulates captured by six insulin-like growth factor binding proteins (IGFBP-1 to -6), most of that in a ~150 kDa ternary complex with IGFBP-3 and the acid-labile subunit. Only the small unbound fraction can engage the type 1 IGF receptor. LR3-IGF-1 is built to defeat that system. Two modifications are made to the 70-residue mature IGF-1 chain: glutamate at position 3 is replaced by arginine, and a 13-residue N-terminal extension is appended. Per the original Francis 1992 description, that extension comprises the first eleven amino acids of methionyl porcine growth hormone followed by a Val-Asn linker, giving the sequence MFPAMPLSSLFVN. The combination substantially reduces IGFBP affinity, so a far larger fraction of the molecule is receptor-available.
Receptor engagement itself is entirely conventional. LR3-IGF-1 is a full agonist at the IGF-1 receptor (IGF-1R), a disulfide-linked receptor tyrosine kinase of the insulin receptor family. Ligand binding drives trans-autophosphorylation of the beta-subunit kinase domains and recruitment of IRS-1/IRS-2 and Shc. Two arms follow: PI3K to AKT to mTORC1, which phosphorylates S6K1 and 4E-BP1 to raise translation rates and simultaneously phosphorylates FoxO transcription factors to suppress the atrogene programme (MuRF1, atrogin-1/MAFbx); and Ras to Raf to MEK to ERK1/2, which drives proliferation. In skeletal muscle the AKT-mTORC1 arm carries the hypertrophic signal. Because IGF-1R and the insulin receptor are closely homologous and assemble into functional hybrid receptors, IGF-1 analogues also cross-activate the insulin receptor at sufficient free concentration, which is the direct origin of the hypoglycaemia risk.
The engineering is both the point and the problem. The IGFBP system is not an inconvenience to be bypassed; it is the mechanism by which the body restricts IGF-1 signalling to the right tissue at the right time, and by which it prevents IGF-1 from acting as an insulin mimetic. Removing that buffer produces an unbuffered, systemically available IGF-1R agonist. That property is genuinely useful in a bioreactor, where the goal is maximal proliferative and anti-apoptotic signalling in a mammalian production cell line. It is a liability in a whole organism.
What the research shows
LR3-IGF-1 was characterised by Francis and colleagues in Adelaide in 1992 as one of a family of N-terminally extended IGF-1 analogues built to dissect how much of IGF-1's biological potency is controlled by binding proteins rather than by receptor affinity. Their answer was: most of it. The published potency ranking in cell lines that secrete IGFBPs was Long [Arg3]-IGF-I and des(1-3)IGF-I greater than Long [Gly3]-IGF-I greater than Long IGF-I greater than native IGF-I. The decisive control is often overlooked: in chicken embryo fibroblasts, which secrete no detectable IGFBPs, Long [Arg3]-IGF-I was actually less potent than native IGF-1. The potency advantage is a property of the binding-protein environment, not of the receptor. The analogue then became a commercial serum-free cell-culture supplement, which is where the overwhelming majority of the tonnage produced still goes.
The animal literature is real but narrow and old, and almost none of it is about athletic muscle growth. Rats given IGF-1 variants alongside dexamethasone showed anabolic responses that native IGF-1 did not produce. Infusion in guinea pigs stimulated organ growth but simultaneously reduced plasma IGF-1, IGF-2 and IGFBP concentrations, a negative-feedback effect that is rarely mentioned by sellers. In neonatal calves, LR3-IGF-1 modulated the somatotropic axis, with effects dependent on nutritional state. These are nutrition and catabolic-illness models in growing animals, not resistance-training models in adults.
What does not exist is the part that matters. ClinicalTrials.gov returns no interventional study of LR3-IGF-1 in humans, at any phase, for any indication, and PubMed contains no human administration study. Every claim that LR3-IGF-1 increases lean mass, accelerates recovery or induces muscle hyperplasia in people is extrapolation from rodents and cell culture, or anecdote. The one human-relevant analytical finding is sobering: when Kohler and colleagues characterised a black-market injection vial sold as Long R3 IGF-1, they found the protein carried an intact hexahistidine purification tag joined by a Leu-Glu linker, an unpurified biotechnology by-product packaged for injection, whose effects in humans are entirely unknown.
Evidence assessment
Preclinical only
Every surviving citation is in vitro, rodent or livestock work plus one analytical characterisation of a seized vial; there is no registered interventional clinical trial and no published human administration study.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency Preclinical only
In cell lines secreting IGF binding proteins the potency order was Long [Arg3]-IGF-I and des(1-3)IGF-I > Long [Gly3]-IGF-I > Long IGF-I > IGF-I; in IGFBP-free chicken embryo fibroblasts Long [Arg3]-IGF-I was less potent than IGF-I, showing the potency gain derives from reduced IGFBP interaction rather than improved receptor binding.
Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins Preclinical only
Describes the bacterial expression and purification route for the Glu3-substituted IGF-1 analogues that underpin commercial LR3-IGF-1.
Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats Preclinical only
N-terminally modified IGF-1 variants produced anabolic effects on nitrogen balance and muscle protein in dexamethasone-treated rats that native IGF-1 did not achieve at comparable doses.
Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig Preclinical only
Organ growth increased, while plasma IGF-1, IGF-2 and IGF binding protein concentrations fell, indicating suppression of the host somatotropic axis.
The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long-R3-IGF-I Preclinical only
LR3-IGF-1 altered somatotropic axis markers in a large-animal model, with effects dependent on nutritional state.
Detection of His-tagged Long-R3-IGF-I in a black market product Limited evidence
The product contained Long-R3-IGF-I still bearing a hexahistidine purification tag attached via a Leu-Glu linker, indicating an unpurified laboratory by-product sold for injection.
Safety
There is no human safety dataset for LR3-IGF-1. The nearest legitimate proxy is mecasermin, recombinant human IGF-1, which is licensed for severe primary IGF-1 deficiency and whose label reports hypoglycaemia in a large proportion of treated children, tonsillar and adenoidal hypertrophy sometimes requiring surgery, lymphoid tissue hypertrophy, injection-site lipohypertrophy, hypersensitivity reactions, raised intracranial pressure with papilloedema, and slipped capital femoral epiphysis. LR3-IGF-1 removes the IGFBP buffer that partly restrains those effects, so acute hypoglycaemia risk per unit administered is if anything higher, and it comes on faster.
Beyond the acute picture, IGF-1R signalling is mitogenic and anti-apoptotic by design. Observational epidemiology consistently links higher circulating IGF-1 to modestly increased risk of prostate, breast and colorectal cancer, and Mendelian randomisation work supports a causal contribution for at least some of those sites. That is a reason for caution about sustained supraphysiological IGF-1R agonism in adults, not proof of harm from any particular exposure. Cardiac hypertrophy and acromegalic soft-tissue changes are plausible on the same reasoning but undocumented for this analogue. Immunogenicity is a genuine and unstudied concern: LR3-IGF-1 carries a non-human sequence at its N-terminus, is produced in Escherichia coli, and anti-drug antibodies could in principle cross-react with endogenous IGF-1.
Product quality is a separate hazard and, on the available evidence, not a hypothetical one. The published analysis of a black-market vial found a His-tagged research by-product rather than a purified therapeutic. E. coli-expressed proteins sold outside a pharmaceutical quality system carry endotoxin, host-cell protein and misfolding risks that no certificate of analysis from an unregulated vendor meaningfully addresses.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. IGF-1 products are prescription-only medicines; supplying an unlicensed medicinal product for human use, or advertising a prescription-only medicine to the public, breaches the Human Medicines Regulations 2012, and MHRA has taken enforcement action against online sellers of unlicensed injectables. IGF-1 and its analogues are not controlled under the Misuse of Drugs Act 1971, unlike somatropin (growth hormone) and chorionic gonadotrophin, which are Class C. Legitimate supply as a laboratory reagent is unaffected, provided it is not offered for human administration. |
| United States | Not approved by FDA for any indication and not the subject of any active investigational new drug application. It is not a dietary supplement: FDA's position is that peptide and protein drugs of this kind fall outside the dietary supplement definition, so marketing them for human use renders them unapproved new drugs and misbranded under the Federal Food, Drug, and Cosmetic Act. FDA has issued warning letters to online research-peptide retailers on exactly that basis. LR3-IGF-1 is legitimately sold as a cell-culture reagent. Mecasermin (recombinant human IGF-1) is the only FDA-approved IGF-1 product and is a different molecule. Not scheduled by DEA. |
| WADA (sport) | Prohibited at all times, in and out of competition. The WADA Prohibited List, section S2.3 (Growth Factors and Growth Factor Modulators), covers 'Insulin-like Growth Factor-1 (IGF-1) and its analogues'. Substances in class S2 are non-Specified Substances, which carries the heavier sanction bracket. Mass-spectrometry methods for detecting Long-R3-IGF-I in seized products have been published (Kohler et al., 2010). |
Questions
In cell systems that contain IGF binding proteins, yes, but not for the reason most people assume. Francis and colleagues showed in 1992 that in binding-protein-free chicken embryo fibroblasts, Long [Arg3]-IGF-I was actually less potent than native IGF-1. The apparent potency gain comes almost entirely from evading the IGF binding proteins that normally sequester over 98% of circulating IGF-1, not from better receptor engagement. In a human being, that same property removes a physiological safety buffer rather than simply amplifying a benefit.
No. A search of ClinicalTrials.gov returns no registered interventional trial of Long R3 IGF-1 in humans at any phase, and PubMed contains no human administration study. The compound was developed as a cell-culture reagent for biopharmaceutical manufacturing and was never taken into clinical development. Claims about its effects on human muscle are extrapolated from rodents, livestock and cell lines.
Mecasermin is recombinant human IGF-1, the identical native 70-residue sequence, and is a licensed medicine for severe primary IGF-1 deficiency with a full regulatory dossier and a known adverse-event profile. LR3-IGF-1 is a different molecule: 83 residues, with arginine substituted at position 3 and a 13-residue N-terminal extension derived from methionyl porcine growth hormone plus a Val-Asn linker. It has no approval anywhere and no human data. They are not interchangeable.
It makes it saleable, which is not the same thing. The label is a commercial and legal shield: it lets vendors distribute an unapproved drug substance while disclaiming the human use they know is intended. In the US, FDA's position is that marketing such a product for human consumption makes it an unapproved new drug and misbranded, and warning letters have been issued on that basis. In the UK, supplying it for human use without a marketing authorisation breaches the Human Medicines Regulations 2012. The label also carries no quality guarantee: one published analysis of a black-market vial found an unpurified, His-tagged research by-product.